WHO Model Prescribing Information: Drugs Used in Anaesthesia
(1989; 60 pages) [French] Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Ouvrir ce répertoire et afficher son contenuPremedication
Ouvrir ce répertoire et afficher son contenuGeneral anaesthetics and oxygen
Fermer ce répertoireLocal anaesthetics
Afficher le documentBupivacaine
Afficher le documentLidocaine
Afficher le documentTetracaine
Afficher le documentEpinephrine (for use with local anaesthetics)
Ouvrir ce répertoire et afficher son contenuNon-opioid analgesics
Ouvrir ce répertoire et afficher son contenuOpioid analgesics and antagonists
Ouvrir ce répertoire et afficher son contenuMuscle relaxants and cholinesterase inhibitors
Ouvrir ce répertoire et afficher son contenuBlood substitutes
Ouvrir ce répertoire et afficher son contenuSolutions for correcting water and electrolyte imbalance
Ouvrir ce répertoire et afficher son contenuAntacid for use in obstetric practice
Afficher le documentAnaesthesia at the District Hospital
Afficher le documentSelected WHO publications of related interest
Afficher le documentBack cover


Group: local anaesthetic agent
Solution (eye drops): 5 mg (hydrochloride)/ml (0.5%)

General information

Tetracaine is a local anaesthetic that penetrates the cornea and conjunctiva. It is effective after topical application to the eye within 30 seconds and anaesthesia persists for at least 15 minutes.

Clinical information


Short-lasting local anaesthesia of the cornea and conjunctiva.

Dosage and administration

One or 2 drops of 0.5% solution should be instilled into the conjunctival sac.


• Known hypersensitivity to tetracaine.
• Ocular inflammation or infection.


The anaesthetized eye should be protected from dust and bacteriological contamination until sensation is fully restored.

Prolonged use has resulted in corneal opacities.

Adverse effects

A localized burning sensation may occur and, more rarely, lacrimation and photophobia.


Tetracaine eye drops should be kept in well-closed containers protected from light, and should not be allowed to freeze.

vers la section précédente
vers la section suivante
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 29 octobre 2018